(Q33914512)

30 July 2017

Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients (English)

1 reference

30 July 2017

1 reference

Denis Lane

1

1 reference

30 July 2017

Isabelle Matte

series ordinal

2

1 reference

30 July 2017

Claudine Rancourt

series ordinal

3

1 reference

30 July 2017

Alain Piché

series ordinal

4

1 reference

30 July 2017

language of work or name

English

0 references

publication date

30 May 2011

1 reference

30 July 2017

1 reference

30 July 2017

11

1 reference

30 July 2017

210

1 reference

https://scigraph.springernature.com/pub.10.1186/1471-2407-11-210

30 July 2017

0 references

cites work

Cancer-associated fibroblasts and their putative role in potentiating the initiation and development of epithelial ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3118896

IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3118896

Stress effects on FosB- and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3118896

Effects of siltuximab on the IL-6-induced signaling pathway in ovarian cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3118896

Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3118896

Ovarian cancer ascites protects from TRAIL-induced cell death through alphavbeta5 integrin-mediated focal adhesion kinase and Akt activation

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3118896

The prosurvival activity of ascites against TRAIL is associated with a shorter disease-free interval in patients with ovarian cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3118896

Characterization of ovarian cancer ascites on cell invasion, proliferation, spheroid formation, and gene expression in an in vitro model of epithelial ovarian cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3118896

Malignant ascites protect against TRAIL-induced apoptosis by activating the PI3K/Akt pathway in human ovarian carcinoma cells

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3118896

Common polymorphism in interleukin 6 influences survival of women with ovarian and peritoneal carcinoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3118896

Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3118896

B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3118896

Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3118896

Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3118896

Ascites induces modulation of alpha6beta1 integrin and urokinase plasminogen activator receptor expression and associated functions in ovarian carcinoma.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3118896

Lysophosphatidic acid (LPA) in malignant ascites stimulates motility of human pancreatic cancer cells through LPA1.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3118896

Reproductive hormone-induced, STAT3-mediated interleukin 6 action in normal and malignant human ovarian surface epithelial cells

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3118896

Epithelial ovarian cancer: prevention, diagnosis, and treatment

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3118896

Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3118896

Regulation of spontaneous and TNF/IFN-induced IL-6 expression in two human ovarian-carcinoma cell lines.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3118896

Differential regulation of IL-6 promoter activity in a human ovarian-tumor cell line transfected with various p53 mutants: involvement of AP-1.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3118896

Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3118896

Autocrine and paracrine functions of cytokines in malignant lymphomas

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3118896

Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3118896

A putative new growth factor in ascitic fluid from ovarian cancer patients: identification, characterization, and mechanism of action

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3118896

Ascitic fluid from human ovarian cancer patients contains growth factors necessary for intraperitoneal growth of human ovarian adenocarcinoma cells

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3118896

Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovarian tumor cultures

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3118896

Malignant ascites fluid (MAF), including ovarian-cancer-associated MAF, contains angiostatin and other factor(s) which inhibit angiogenesis.

5 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1471-2407-11-210

Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1471-2407-11-210

-Cytokine level in malignant ascites and peripheral blood of patients with advanced ovarian carcinoma-

21 January 2018

1 reference

12 December 2020

Cytokine production profiles in the peritoneal fluids of patients with malignant or benign gynecologic tumors

1 reference

12 December 2020

Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients

1 reference

12 December 2020

Preoperative and postoperative cytokines in patients with cancer

1 reference

12 December 2020

Stimulation of ovarian tumor cell proliferation with monocyte products including interleukin-1, interleukin-6, and tumor necrosis factor-α

1 reference

12 December 2020

Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity

1 reference

12 December 2020

Effects of interleukin-6 on in vitro cell attachment, migration and invasion of human ovarian carcinoma

1 reference

12 December 2020

Cytokine analysis as a tool to understand tumour–host interaction in ovarian cancer

1 reference

12 December 2020

Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer

1 reference

12 December 2020

IL-6 secretion by human peritoneal mesothelial and ovarian cancer cells

1 reference

12 December 2020

Serum evaluation of interleukin 6 in ovarian cancer patients

1 reference

12 December 2020

Ascites as a predictor of ovarian malignancy

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-2407-11-210

1 reference

Dimensions Publication ID

30 July 2017

0 references

1 reference

30 July 2017

1 reference